Bausch & Lomb
Bausch & Lomb's revenue rose 6.5% to $5.1 billion in fiscal 2025. Its operating margin was 2.2%, down from 3.4% a year earlier. Free cash flow was −$66 million. The diluted share count rose 0.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Bausch & Lomb does
Bausch + Lomb sells products for eye health in about 100 countries. Its portfolio of about 400 products includes contact lenses, lens care products, intraocular lenses (artificial lenses implanted in the eye), surgical systems and devices, prescription eye medicines, vitamins and mineral supplements, and other consumer products. It has about 13,000 employees.
It sells to consumers through stores and online, and to eye doctors, surgeons and hospitals. It says its range covers nearly all areas of the eye health market, and it competes with other eye health and medical device companies in each of them.
The company was founded in 1853 and is a subsidiary of Bausch Health Companies (BHC), which holds about 88% of its shares. Its shares began trading on the NYSE and the Toronto Stock Exchange in May 2022. BHC has said it still wants to separate the two companies, by selling its stake, selling Bausch + Lomb or giving the shares to its own shareholders, but there is no assurance that this will happen.
Its biggest risks, as it describes them
- BHC's separation plan may not be completed or may not bring the expected benefits.
- BHC controls the direction of the business until the separation is complete.
- Product liability claims if its products are said to have caused harm.
- Impairment of its large goodwill and other intangible assets, which could hurt profits.
- Legal and government proceedings that are costly and uncertain.
Income statement
From fiscal 2021 to 2022, earnings per share fell 96.2% a year and net income 96.7% a year, with the share count about the same. Bausch & Lomb then lost money in fiscal 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 174 | 354 | 331 | 305 | 383 |
| Debt incl. finance leases | 0 | 2,436 | 4,562 | 4,784 | 5,048 |
| Net debt (negative means net cash) | −174 | 2,082 | 4,231 | 4,479 | 4,665 |
| Net debt to EBITDA | −0.2x | 3.5x | 8.3x | 7.5x | 8.7x |
| Debt to equity | 0.0x | 0.3x | 0.7x | 0.7x | 0.8x |
| Interest coverage | — | 1.4x | 0.5x | 0.4x | 0.3x |
| Current ratio | 1.5x | 1.6x | 1.7x | 1.6x | 1.6x |
| Quick ratio | 1.0x | 1.2x | 1.1x | 1.0x | 1.0x |
Cash flow
Projections
Project Bausch & Lomb's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 9 insiders bought $1.2 million of Bausch & Lomb shares on the open market, and 2 insiders sold $1.2 million.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 10, 2026 | Frederick MunschSVP, Controller and CAO | Sold | 52,900 | $16.78 | $887,662 | Form 4 |
| Aug 7, 2026 | Eschenbach Andrew C. VonDirector | Sold | 6,059 | $16.58 | $100,458 | Form 4 |
| Aug 6, 2026 | Eschenbach Andrew C. VonDirector | Sold | 12,500 | $16.50 | $206,250 | Form 4 |
| Mar 6, 2026 | Brent L SaundersCEO and Chairman of the Board, Director | Bought | 14,700 | $17.14 | $251,958 | Form 4 |
| Mar 6, 2026 | A Robert D BaileyEVP & Chief Legal Officer | Bought | 14,600 | $17.15 | $250,390 | Form 4 |
| Mar 6, 2026 | Sam EldessoukyEVP and CFO | Bought | 4,000 | $17.13 | $68,520 | Form 4 |
| Mar 3, 2026 | Thomas W. Ross Sr.Director | Bought | 4,500 | $17.68 | $79,560 | Form 4 |
| Mar 2, 2026 | Eduardo AlfonsoDirector | Bought | 4,300 | $17.90 | $76,970 | Form 4 |
| Feb 27, 2026 | Eschenbach Andrew C. VonDirector | Bought | 4,364 | $18.31 | $79,905 | Form 4 |
| Feb 23, 2026 | Steven H CollisDirector | Bought | 15,000 | $17.81 | $267,150 | Form 4 |
| Feb 20, 2026 | Russel C RobertsonDirector | Bought | 4,400 | $17.90 | $78,760 | Form 4 |
| Feb 19, 2026 | Karen LingDirector | Bought | 4,000 | $17.74 | $70,960 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 8 | 3 of 8 | 3 of 8 |
| Rule of 40 | 5.3% | 14.3% | 5.2% |
| Altman Z'' | 1.69 | 1.45 | 1.24 |
| Accruals ratio | −2.0% | −4.1% | −4.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Pass | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Fail | Pass |
| F-score | 3 of 8 | 3 of 8 | 3 of 8 |
Compare
Put Bausch & Lomb side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Bausch & Lomb | FY25 | 6.5% | 2.2% | −1.3% | 0.8% | 8.7x | 3 | |
| Cooper Companies | FY25 | 5.1% | 16.7% | 10.6% | 4.3% | 2.3x | 5 | Compare |
| Align Technology | FY25 | 0.9% | 13.5% | 12.2% | 13.3% | −1.4x | 5 | Compare |
| Dentsply Sirona | FY25 | −3.0% | −11.5% | 2.8% | −9.9% | — | 6 | Compare |
| West Pharmaceutical Services | FY25 | 6.2% | 19.0% | 15.2% | 18.7% | −0.8x | 9 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 3,412 | 3,765 | 3,768 | 4,146 | 4,791 | 5,101 |
| Revenue growth | — | 10.3% | 0.1% | 10.0% | 15.6% | 6.5% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 253 | 271 | 307 | 324 | 343 | 371 |
| Operating income | 260 | 329 | 207 | 130 | 162 | 113 |
| Net income | −18 | 182 | 6 | −260 | −317 | −360 |
| Diluted EPS (US$) | −0.05 | 0.52 | 0.02 | −0.74 | −0.90 | −1.02 |
| Diluted shares (millions) | 350 | 350 | 350 | 350 | 352 | 354 |
| Cash flow | ||||||
| Cash from operations | 522 | 873 | 345 | −17 | 232 | 283 |
| Capital expenditure | 253 | 193 | 175 | 181 | 291 | 349 |
| Free cash flow | 269 | 680 | 170 | −198 | −59 | −66 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 50 | 62 | 62 | 74 | 92 | 149 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 238 | 174 | 354 | 331 | 305 | 383 |
| Debt incl. finance leases | — | 0 | 2,436 | 4,562 | 4,784 | 5,048 |
| Total assets | — | 10,823 | 11,144 | 13,442 | 13,469 | 14,022 |
| Total liabilities | — | 1,421 | 4,043 | 6,522 | 6,925 | 7,503 |
| Shareholders' equity | 9,988 | 9,329 | 7,033 | 6,850 | 6,473 | 6,448 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | 7.6% | 8.7% | 5.5% | 3.1% | 3.4% | 2.2% |
| Net margin | −0.5% | 4.8% | 0.2% | −6.3% | −6.6% | −7.1% |
| Free cash flow margin | 7.9% | 18.1% | 4.5% | −4.8% | −1.2% | −1.3% |
| Rule of 40 (growth + FCF margin) | — | 28.4% | 4.6% | 5.3% | 14.3% | 5.2% |
| Return on capital | — | — | 1.1% | 1.0% | 1.1% | 0.8% |
| Return on equity | — | — | 0.1% | −3.8% | −4.8% | −5.6% |
| Return on assets | — | — | 0.1% | −2.1% | −2.4% | −2.6% |
| Net debt to EBITDA | — | −0.2x | 3.5x | 8.3x | 7.5x | 8.7x |